Biogen Idec, Fondazione Telethon and Ospedale San Raffaele have entered into a worldwide collaboration to jointly develop gene therapies for the treatment of both hemophilia A and B Read the full story

Biogen Idec plans to leverage Convergence’s expertise in chronic pain research and clinical development to accelerate the growth of its pain portfolio Read the full story

Swedish Orphan Biovitrum has elected to add the preclinical rFVIIIFc-XTEN-vWF fusion molecule to the company's pharma deal with Biogen Idec. Read the full story

The term 'top pharma' can relate to the top pharmaceutical companies or the top 10 or 50... Read the full story

Biogen Idec is a top pharmaceutical/biotechnology company based in Weston, MA, USA Read the full story

Eisai and Biogen Idec have entered into a pharma deal to develop and commercialize two of Eisai’s clinical candidates for Alzheimer’s disease (AD), E2609 and BAN2401. Read the full story

Biogen Idec and UCB have signed exclusive pharma alliance agreements granting UCB the right to commercialize Biogen Idec products. Read the full story

Biogen Idec and Sangamo BioSciences announced an exclusive worldwide Pharma licensing and collaboration agreement focused on the development of therapeutics for hemoglobinopathies for $320 million. Read the full story

A pharma alliances is created between Biogen Idec and Proteostasis Therapeutics for Alzheimer's treatment. Read the full story

Amicus Therapeutics has entered a collaboration with pharma partners Biogen Idec to discover, develop and commercialize novel small molecules for the treatment of Parkinson's disease. Read the full story